FDA OKs AbbVie's pan-genotypic HCV med Mavyret

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

The FDA approves AbbVie's (ABBV +0.3%) Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with genotype 1 - 6 chronic hepatitis C virus (HCV) infection without cirrhosis or with mild cirrhosis, including patients with moderate-to-severe kidney disease and those on dialysis.

Breakthrough Therapy-tagged Mavyret is approved as a once-daily, three-tablet, eight-week regimen in treatment-naive patients with all genotypes without cirrhosis.

Rival Gilead Sciences (GILD -1.2%) is under modest pressure on the news.

Subscribe for full text news in your inbox